Insight

Racial Disparities in ctDNA Profiles and Targeted Therapy in mBC – International Society of Liquid Biopsy

Breast Cancer/canceronco.com

Mar 3, 2025, 11:36

Racial Disparities in ctDNA Profiles and Targeted Therapy in mBC – International Society of Liquid Biopsy

International Society of Liquid Biopsy (ISLB) shared a post on X about a paper by Emily Podany et al. published in JAMA Network Open:

“Racial Disparities in ctDNA Profiles and Targeted Therapy in Metastatic Breast Cancer.

Key Findings:

Black patients had higher GATA3 and CCND2 mutations vs. White patients.
Lower use of PI3K inhibitors in Black patients (5.9% vs. 28.8%), despite mutations.
Shorter overall survival (OS) in Black patients, highlighting inequities.
Barriers include clinical trial exclusion, socioeconomic factors and access gaps.

Equitable access to precision oncology and clinical trials is critical!”

“Racial Differences in ctDNA Profiles, Targeted Therapy Use, and Outcomes in Metastatic Breast Cancer”

Authors: Emily Podany, Lorenzo Foffano, Lorenzo Gerratana, Massimo Cristofanilli, Andrew Davis et al.

Racial Disparities in ctDNA Profiles and Targeted Therapy in mBC - International Society of Liquid Biopsy

More posts featuring ISLB.

Andrew Davis cancer Emily Podany International Society of Liquid Biopsy ISLB Lorenzo Foffano Lorenzo Gerratana Massimo Cristofanilli MBC metastatic breast cancer OncoDaily Oncology

Beyond the Red Carpet: Oscar Winners and Nominees Who Fought Cancer

Oncologist Near Me – Lidia Schapira: A Leader in Cancer Care and Medical Education

Dr. Manette Le Grange joins OncoDaily Editorial Board

FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Standard of Care as Perioperative Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

New Paper Alert Real-Life Impact of Enfortumab Vedotin or Chemotherapy in the Sequential Treatment of Advanced Urothelial Carcinoma: The ARON-2 Retrospective Experience